Lowest price guarantee and savings with every new order!

Categories

FREE UK DELIVERY

On all orders over £240

Daklinza (Daclatasvir)

General Info Hide Show

Daklinza

Daklinza is an antiviral drug indicated as a part of concomitant therapy of chronic hepatitis C virus (HCV) infection in patients with either compensated or decompensated liver disease (including cirrhosis). The medication is a direct agent against chronic HCV genotype 1 or 3 and is to be used with other medicines to prevent multiplication and spread of the virus in the body. Daklinza is appropriate for administration in adults 18 years of age and over.

UK Mail, Reg.Mail Royal Mail, EMS

Approximate Delivery Date:
August, 05 - August, 14
Approximate Delivery Date:
July, 23 - July, 29

In Stock

Daklinza 60mg; 28 pills bottle

1 bottle
£437.56 per bottle
£437.56 £546.95 per bottle
2 bottles
£343.08 per bottle
£686.16 £857.69 per 2 bottles
£686.16 Add to Basket You Save: £188.97

Latest Daklinza Reviews:

General Info

Daklinza is an antiviral drug indicated as a part of concomitant therapy of chronic hepatitis C virus (HCV) infection in patients with either compensated or decompensated liver disease (including cirrhosis). The medication is a direct agent against chronic HCV genotype 1 or 3 and is to be used with other medicines to prevent multiplication and spread of the virus in the body. Daklinza is appropriate for administration in adults 18 years of age and over.

Daklinza
Active Ingredient

Daclatasvir.

Description

Daklinza is a direct-acting antiviral medicine indicated for the treatment of a long-term infection caused by the hepatitis C virus (HCV) genotype 1 or 3 in patients with compensated or decompensated liver disease. It is used exclusively as a part of a concomitant HCV treatment with such medicines as Sofosbuvir and Ribavirin.

The medication contains the active ingredient Daclatasvir which belongs to a group of drugs called nonstructural protein 5A (NS5A) complex inhibitors. It works by preventing the hepatitis C virus from copying itself and infecting liver cells. This helps to decrease the amount of the virus in the body and promotes its removal from the human blood over a period of time.

Daklinza is only effective in combination with other antiviral agents and at evenly spaced intervals. Together they help the immune system fight the infection and promote recovery and better functioning of the liver. Patients should be aware that anti-hepatitis C combination treatment does not prevent from passing the virus to the others. In order to lower such a risk, needle sharing or/and practice of ‘unsafe sex’ (without any contraceptive measures) should be avoided.

Indications

Concomitant treatment of patients with chronic HCV genotypes 1 and 3 infections with/without compensated or decompensated liver disease (including cirrhosis).

MOA (mechanism of action)

Daclatasvir is a first-in-class HCV NS5A replication complex inhibitor and a selective direct-acting antiviral (DAA) agent. The active substance exerts the ability of binding to HCV RNA and interfering with the activity of a nonstructural protein 5A (NS5A), a vital component for the hepatitis C virus replication process. This leads to an inhibition of the two HCV life cycle stages - viral RNA replication and virion assembly which results in the viral RNA chain termination.

Dosage

Treatment with Daklinza should be initiated and monitored by a doctor for each individually. Before starting the therapy, patients should be tested for the evidence of current or prior hepatitis B virus (HBV) infection and/or any drug resistance. Daklinza is to be taken orally with or without food. The tablets must be swallowed whole with a glassful of water. Do not chew or crush them.

Maximum daily dose of Daklinza for genotype 1 or 3 HCV infection - 90 mg.

In regimens of chronic HCV infection treatment, the medicine may be administered with or without Ribavirin. When taken with, the dosing should be advised and adjusted by a doctor basing on a patient’s hemoglobin levels and creatinine clearance as well as on the body weight. However, if the administration of Sofosbuvir is discontinued in those receiving Daclatasvir together with Sofosbuvir, then Daclatasvir intake should be ceased too. Avoid stopping any drugs intake too early as it may result in the infection retrieval.

Missed dose

If you miss a dose of Daklinza you should take it as soon as you remember. If it is the time for the next dose you should continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

Overdose

If an overdose occurs and you are feeling unwell, you should seek emergency medical attention or contact your healthcare provider immediately.

Storage

Store at room temperature between 20°C and 25°C (68°F and 77°F) away from excess moisture and heat. Do not use the medication if the seal is missing or broken. Keep the bottle tightly closed. Throw away any unused medicine after the expiration date. Keep out of the reach of children.

Safety Information

Side effects

The most common side effects associated with Daklinza are:

  • headache
  • dizziness
  • fatigue
  • confusion
  • insomnia
  • nausea
  • diarrhea
  • vomiting
  • constipation
  • abdominal pain
  • decreased appetite
  • low red blood cell count (anemia)
  • slow heart rate (bradycardia)
  • shortness of breath
  • cough
  • chest pain
  • allergic reactions (dry skin, rash, itching)
  • muscle and joint pain

Side effect occurrence does not only depend on medication you are taking but also on your overall health and other factors.

Contraindications

Do not use Daklinza in patients with known hypersensitivity to Daclatasvir or any of the drug's excipients.

Do not take the medication as a monotherapy for the chronic hepatitis C virus (HCV) treatment.

Do not use the drug if you have been infected with hepatitis B virus (HBV) as the treatment of chronic HCV infection may increase the replication of HBV.

Do not give the tablets to patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.

Do not take the medicine if you are pregnant or breastfeeding unless recommended by your doctor.

Do not give Daklinza to patients younger than 18 years of age without a doctor’s advice.

Do not co-administrate Daklinza with any of the following medications:

  • anticonvulsants (e.g., carbamazepine, eslicarbazepine, fosphenytoin, phenytoin, phenobarbital, oxcarbazepine, pentobarbital, primidone)
  • medicines for the treatment of tuberculosis (such as rifampicin, rifabutin or rifampin)
  • cardiovascular drugs (amiodarone)
  • steroids used to treat allergic and inflammatory diseases (as dexamethasone)
  • medications containing St John's wort
  • some other drugs (like dabrafenib, enzalutamide, lumacaftor, mitotane, nevirapine)

Caution should be exercised when Daklinza is taken concomitantly with P-gp, OATP 1B1 or 1B3, or BCRP as it may increase or prolong the therapeutic effect of these drugs and/or increase chances for side effects occurrence.

Delivery Information
Destination Service Tracking Delivery Time Price
Worldwide Not trackable 14-21 working days £12.00 per order
Trackable, where available 5-9 working days £20.00 per order

Your order will be packed safely and dispatched within 24 hours.

view

This is how exactly your parcel looks like. It is similar to a regular private letter, which does not disclose its contents. Size: 9.4x4.3x0.3 inches (24x11x0.7cm).

OFFER OF
THE WEEK

Soft Discount Pack

Erectile Problems? Soft Discount Pack x 180 pills Viagra Soft free

£98.00 £204.16 Shop Now
52% OFF
Do not show "Last Viewed"

Last Viewed

Daklinza

Daklinza

Daklinza is an antiviral drug indicated as a part of concomitant therapy of chronic h...

£343.08 per bottle £428.85
Trust Pilot RPS CQC Sage-Pay Norton

Discount Coupon